HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice

Journal of Immune Based Therapies and Vaccines

Volumn 8, Issue , 2010, Pages

  Pillay, Sirika ^a,b   Shephard, Enid G ^b   Meyers, Ann E ^a,b   Williamson, Anna Lise ^b,c   Rybicki, Edward P ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; NEF PROTEIN; PR55GAG PROTEIN; PR55GAG REVERSE TRANSCRIPTASE FUSION PROTEIN; PR55GAG TAT NEF FUSION PROTEIN; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOUSE; NONHUMAN; VIRUS LIKE AGENT;

EID: 78349301281     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-8-7     Document Type: Article

References (23)

1. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006, 80(18):9134-9143. 10.1128/JVI.00050-06, 1563937, 16940524.
2. Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 2009, 27(35):4857-4866. 10.1016/j.vaccine.2009.05.064, 19520196.
3. Amara RR, Sharma S, Patel M, Smith JM, Chennareddi L, Herndon JG, Robinson HL. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques. Virology 2005, 334(1):124-133. 10.1016/j.virol.2005.01.026, 15749128.
4. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005, 42(2):259-277. 10.1016/j.molimm.2004.06.028, 15488613.
5. Jaffray A, Shephard E, van Harmelen J, Williamson C, Williamson AL, Rybicki EP. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 2004, 85(Pt 2):409-413. 10.1099/vir.0.19396-0, 14769898.
6. Ye L, Wen Z, Dong K, Pan L, Bu Z, Compans RW, Zhang H, Yang C. Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses. J Biomed Biotechnol 2010, 497219. 2876254, 20508832.
7. Zanotto C, Elli V, Basavecchia V, Brivio A, Paganini M, Pinna D, Vicenzi E, De Giuli Morghen C, Radaelli A. Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting. FEMS Immunol Med Microbiol 2003, 35(1):59-65. 10.1111/j.1574-695X.2003.tb00649.x, 12589958.
8. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25(2):98-104. 10.1016/j.it.2003.11.009, 15102369.
9. Scriba TJ, zur Megede J, Glashoff RH, Treurnicht FK, Barnett SW, van Rensburg EJ. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine 2005, 23(9):1158-1169. 10.1016/j.vaccine.2004.08.026, 15629359.
10. Nkolola JP, Wee EG, Im EJ, Jewell CP, Chen N, Xu XN, McMichael AJ, Hanke T. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 2004, 11(13):1068-1080. 10.1038/sj.gt.3302241, 15164090.
11. Ellenberger D, Wyatt L, Li B, Buge S, Lanier N, Rodriguez IV, Sariol CA, Martinez M, Monsour M, Vogt J, et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 2005, 340(1):21-32. 10.1016/j.virol.2005.06.014, 16023165.
12. Halsey RJ, Tanzer FL, Meyers A, Pillay S, Lynch A, Shephard E, Williamson AL, Rybicki EP. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res 2008, 133(2):259-268. 10.1016/j.virusres.2008.01.012, 18329748.
13. Pacheco SE, Gibbs RA, Ansari-Lari A, Rogers P. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity. AIDS Res Hum Retroviruses 2000, 16(18):2009-2017. 10.1089/088922200750054747, 11153084.
14. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, Hanke T, Williamson AL, Williamson C. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006, 87(Pt 2):399-410. 10.1099/vir.0.81379-0, 16432028.
15. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005, 79(14):8828-8834. 10.1128/JVI.79.14.8828-8834.2005, 1168733, 15994776.
16. Pillay S, Meyers A, Williamson AL, Rybicki EP. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol Prog 2009, 25(4):1153-1160. 10.1002/btpr.187, 19572400.
17. Radaelli A, Bonduelle O, Beggio P, Mahe B, Pozzi E, Elli V, Paganini M, Zanotto C, De Giuli Morghen C, Combadiere B. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 2007, 25(11):2128-2138. 10.1016/j.vaccine.2006.11.009, 17241705.
18. Shephard E, Burgers WA, van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C, Williamson AL. A Multigene HIV Type 1 Subtype C Modified Vaccinia Ankara (MVA) Vaccine Efficiently Boosts Immune Responses to a DNA Vaccine in Mice. AIDS Res Hum Retroviruses 2008, 24(2):207-17. 10.1089/aid.2007.0206, 18240963.
19. Janeway C, Travers P, Walport M, Shlomchik M. Immunology tool box: Appendix I. Immunobiology 5: the immune system in health and disease 2001, New York: Garland Pub, 5.
20. Sadagopal S, Amara RR, Montefiori DC, Wyatt LS, Staprans SI, Kozyr NL, McClure HM, Moss B, Robinson HL. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J Virol 2005, 79(6):3243-3253. 10.1128/JVI.79.6.3243-3253.2005, 1075739, 15731219.
21. Jansen CA, De Cuyper IM, Hooibrink B, van der Bij AK, van Baarle D, Miedema F. Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood 2006, 107(4):1427-1433. 10.1182/blood-2005-07-2907, 16234358.
22. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999, 73(8):6715-6720. 112756, 10400769.
23. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000, 16(3):273-282. 10.1089/088922200309368, 10710215.